PMID- 19249426
OWN - NLM
STAT- MEDLINE
DCOM- 20090331
LR  - 20090302
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 157
IP  - 3
DP  - 2009 Mar
TI  - Intracoronary administration of bone marrow-derived progenitor cells improves 
      left ventricular function in patients at risk for adverse remodeling after acute 
      ST-segment elevation myocardial infarction: results of the Reinfusion of Enriched 
      Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction study 
      (REPAIR-AMI) cardiac magnetic resonance imaging substudy.
PG  - 541-7
LID - 10.1016/j.ahj.2008.11.011 [doi]
AB  - BACKGROUND: Serial cardiac magnetic resonance imaging (CMR) is the reference 
      standard for evaluating left ventricular function, wall motion, and infarct size 
      in patients with acute myocardial infarction, as well as remodeling during 
      follow-up. The cardiac CMR substudy of the randomized multicenter REPAIR-AMI 
      trial (Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute 
      Myocardial Infarction study) aimed at gaining insight into postinfarction left 
      ventricular remodeling processes. METHODS: Consecutive patients with ST-segment 
      elevation myocardial infarction and primary percutaneous coronary intervention 
      were enrolled (n = 204) and randomly assigned to either stem cell therapy (bone 
      marrow-derived progenitor cells [BMC]) or placebo after bone marrow aspiration. 
      In the magnetic resonance imaging substudy, 54 patients completed serial CMR 
      (baseline, 4 and 12 months, respectively) after enrollment (27 BMC, 27 placebo). 
      Image analysis was performed at a central core laboratory. RESULTS: There were no 
      significant differences between the 2 groups with respect to global ejection 
      fraction (EF), end-diastolic volume (EDV), and end-systolic volume (ESV) at 
      baseline. At 12 months, the treatment effect of BMC infusion on EF amounted to 
      2.8 absolute percentage points (P = .26), the progression of EDV at 12 months was 
      less in the BMC group (treatment effect 14 mL, P = .12), and unlike placebo, ESV 
      did not increase (absolute treatment effect 13 mL, P = .08), respectively. In 
      patients with a baseline EF < median (EF < or = 48.9%), BMC administration was 
      associated with a significantly improved EF (+6.6%, P = .01), reduced EDV 
      increase (treatment effect 29.1 mL, P = .02), and abrogation of ESV increase 
      (treatment effect 29.4 mL, P = .01) after 12 months, respectively. CONCLUSION: 
      Intracoronary administration of BMC additionally improved left ventricular 
      function in patients with impaired left ventricular function after ST-segment 
      elevation myocardial infarction despite optimal "state-of-the-art" reperfusion 
      and pharmacologic treatment on 1-year follow-up and beneficially interfered with 
      adverse postinfarction left ventricular remodeling.
FAU - Dill, Thorsten
AU  - Dill T
AD  - Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany. 
      t.dill@kerckhoff-klinik.de
FAU - Schachinger, Volker
AU  - Schachinger V
FAU - Rolf, Andreas
AU  - Rolf A
FAU - Mollmann, Susanne
AU  - Mollmann S
FAU - Thiele, Holger
AU  - Thiele H
FAU - Tillmanns, Harald
AU  - Tillmanns H
FAU - Assmus, Birgit
AU  - Assmus B
FAU - Dimmeler, Stefanie
AU  - Dimmeler S
FAU - Zeiher, Andreas M
AU  - Zeiher AM
FAU - Hamm, Christian
AU  - Hamm C
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20090131
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Humans
MH  - Image Processing, Computer-Assisted
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/physiopathology/*surgery
MH  - *Stem Cell Transplantation
MH  - Stroke Volume
MH  - *Ventricular Function, Left
MH  - Ventricular Remodeling/physiology
MH  - Young Adult
EDAT- 2009/03/03 09:00
MHDA- 2009/04/01 09:00
CRDT- 2009/03/03 09:00
PHST- 2008/04/17 00:00 [received]
PHST- 2008/11/14 00:00 [accepted]
PHST- 2009/03/03 09:00 [entrez]
PHST- 2009/03/03 09:00 [pubmed]
PHST- 2009/04/01 09:00 [medline]
AID - S0002-8703(08)01029-6 [pii]
AID - 10.1016/j.ahj.2008.11.011 [doi]
PST - ppublish
SO  - Am Heart J. 2009 Mar;157(3):541-7. doi: 10.1016/j.ahj.2008.11.011. Epub 2009 Jan 
      31.